Thomas Lundbäck is Senior Director at the AstraZeneca R&D organisation in Gothenburg, where he leads a department within Discovery Sciences focused on in vitro profiling of small molecules, PROTACs, antisense oligonucleotides, and siRNAs. The department supports research in cardiovascular, renal, metabolic, respiratory, and inflammatory diseases, and besides SAR-profiling assays provides also early assessment of drug metabolism and pharmacokinetics (DMPK) globally within AstraZeneca.

With over 30 years of experience in life science research across academia and industry, Dr. Lundbäck earned his PhD in biophysics from Karolinska Institutet and completed postdoctoral research at University College London and Yale University. He began his industry career at Pharmacia & Upjohn (later Biovitrum), before returning to Karolinska Institutet to join Chemical Biology Consortium Sweden (CBCS), where he contributed to the development and adoption of the cellular thermal shift assay in drug discovery and co-published chemical biology related research with multiple academic groups.

https://scholar.google.com/citations?user=mMlYx30AAAAJ

In addition to his role at AstraZeneca, Dr. Lundbäck chairs the steering groups for Chemical Biology Consortium Sweden (CBCS) – a national infrastructure for chemical biology – and the Chemical Biology and Genome Engineering platform at Science for Life Laboratories in Stockholm. He is also a member of the Scientific and Ethics Advisory Board for EU-OPENSCREEN.